TearScience, a Morrisville medical device company, has raised $15 million in debt financing that it plans to use to commercialize the company's treatment for dry eye disease.

The company raised the money from Oxford Finance and Silicon Valley Bank.

In July, TearScience won regulatory approval from the Food and Drug Administration for its LipiFlow system to diagnose and treat a common form of dry-eye disease.

The company, which employs about 30 people, is now shifting from the development stage to making its LipiFlow system and marketing it to eye doctors.

A Raleigh company that sells a blood test to measure patients' risk for heart disease is reviving plans for an initial public offering of stock.

LipoScience wants to raise $86.25 million in an IPO, the company disclosed in a Securities and Exchange Commission filing.

The company first filed IPO plans in 2002, but scrapped them after failing to attract enough interest on Wall Street. This time, LipoScience officials are hoping that having a few more years of steady revenue growth will help sell their story to investors. They're also counting on renewed interest in IPOs.

Founded in 1994 based on research at N.C. State University, LipoScience's main product is the NMR LipoProfile, a diagnostic test that checks the levels of bad cholesterol in the blood.

Becton Dickinson is reportedly sweet on JoCo.

The publicly traded medical-device maker is considering building a warehouse and distribution center in the Johnston County town of Four Oaks.

Local and state officials previously have said that an unnamed company wants to build the facility, which would create 74 jobs and give a boost to a long-delayed industrial park just off Interstate 95.

A fast-growing medical device company in Durham has raised $55 million in venture-capital financing, one of the largest funding hauls by a Triangle business this year.

TransEnterix will use the money to manufacture and market a new device that promises scar-free abdominal surgery to repair hernias or remove gall bladders, ovaries and appendixes.

The device, called the SPIDER System, recently won approval from the Food and Drug Administration. TransEnterix CEO Todd M. Pope expects to begin training physicians how to use it shortly and start selling it by next spring.

"There's a lot of momentum around minimally invasive surgery," he said. "We're always trying to have less pain and trauma for the patient going into surgery. It's been well-received by physicians and investment community."

Chesson Labs of Durham now holds bragging rights only a handful of Triangle medical companies can claim: It won regulatory approval for its first product.

The four-employee company announced today that it won approval from the Food & Drug Administration to market its Nuvaderm liquid bandage. The product is designed to treat minor scrapes, cuts and burns.

"Nuvaderm's clearance is a major milestone for Chesson Labs, but more importantly it is a product developed to improve wound care," said CEO Scott Neuville, in a prepared statement.

Neuville wasn't immediately available for further comment.

Chesson was founded in 2006 and last year raised $3.3 million in financing.